Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Avalo Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 26 | 1 | 28 | +3 |
| Shares | 2.43M | 2 | 1.34M | −1.09M (−44.8%) |
| Value | $862.7K | $1 | $158.9K | −$703.8K (−81.6%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Avalo Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Acadian Asset Management LLC | 283,306 | $34.0K | 0.00% |
| Baader Bank INC | 184,373 | $19.8K | 0.00% |
| Banque Cantonale Vaudoise | 81,000 | $10.0K | 0.00% |
| JustInvest LLC | 37,358 | $4.51K | 0.00% |
| Level Four Advisory Services, LLC | 36,153 | $4.36K | 0.00% |
| Jane Street Group, LLC | 27,482 | $3.32K | 0.00% |
| Susquehanna International Group, LLP | 22,714 | $2.74K | 0.00% |
| Mariner, LLC | 18,582 | $2.24K | 0.00% |
| XTX Topco Ltd | 18,498 | $2.23K | 0.00% |
| Fifth Third Bancorp | 279 | $34 | 0.00% |
Sold out (7)
Institutions that held Avalo Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| VR Adviser, LLC | 1,250,000 | $444.0K |
| Nantahala Capital Management, LLC | 556,202 | $197.6K |
| Millennium Management LLC | 33,933 | $12.1K |
| JPMorgan Chase & Co | 12,993 | $4.62K |
| Commonwealth Equity Services, LLC | 10,762 | $4.00K |
| HRT Financial LP | 13,106 | $4.00K |
| Bank of America Corp | 4,127 | $1.47K |
Not filed for Q3 2023 yet (1)
Institutions that held Avalo Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Kistler-Tiffany Companies, LLC | 2 | $1 |